MA42250A - Conjugués d'anticorps à cystéine modifiée - Google Patents
Conjugués d'anticorps à cystéine modifiéeInfo
- Publication number
- MA42250A MA42250A MA42250A MA42250A MA42250A MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- cysteine
- modified
- modified antibody
- antibody conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne de nouveaux conjugués constitués d'un agent de liaison cellulaire et d'un agent cytotoxique, où l'agent de liaison cellulaire (cba) est lié de manière covalente à l'agent cytotoxique par l'intermédiaire d'une cys modifiée, telle qu'une cys modifiée au niveau du domaine ch3 de la chaîne lourde, à une position correspondant à la position 442 en numérotation eu/ou (ou c442) sur un cba de type anticorps. L'invention porte également sur des méthodes de préparation des conjugués de la présente invention. L'invention concerne, en outre, une composition et des méthodes utilisables pour inhiber une croissance cellulaire anormale ou traiter un trouble prolifératif chez le mammifère à l'aide des conjugués de l'invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186254P | 2015-06-29 | 2015-06-29 | |
US201662338245P | 2016-05-18 | 2016-05-18 | |
US15/195,269 US10898579B2 (en) | 2015-06-29 | 2016-06-28 | Conjugates of cysteine engineered antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42250A true MA42250A (fr) | 2018-05-02 |
MA42250B1 MA42250B1 (fr) | 2020-11-30 |
Family
ID=56409216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42250A MA42250B1 (fr) | 2015-06-29 | 2016-06-28 | Conjugués d'anticorps à cystéine modifiée |
Country Status (24)
Country | Link |
---|---|
US (2) | US10898579B2 (fr) |
EP (2) | EP3313845B1 (fr) |
JP (4) | JP6843080B2 (fr) |
KR (1) | KR20180021176A (fr) |
CN (2) | CN107708810B (fr) |
AR (1) | AR106013A1 (fr) |
AU (2) | AU2016285929B2 (fr) |
CA (1) | CA2988806A1 (fr) |
CY (1) | CY1123606T1 (fr) |
DK (1) | DK3313845T3 (fr) |
ES (1) | ES2832527T3 (fr) |
HK (1) | HK1254782A1 (fr) |
HR (1) | HRP20201790T1 (fr) |
HU (1) | HUE052616T2 (fr) |
LT (1) | LT3313845T (fr) |
MA (1) | MA42250B1 (fr) |
MD (1) | MD3313845T2 (fr) |
PL (1) | PL3313845T3 (fr) |
PT (1) | PT3313845T (fr) |
RS (1) | RS61050B1 (fr) |
RU (1) | RU2733740C2 (fr) |
SI (1) | SI3313845T1 (fr) |
TW (2) | TWI740833B (fr) |
WO (1) | WO2017004025A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
US20170189548A1 (en) * | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
CN110392685B (zh) | 2016-11-23 | 2023-07-04 | 伊缪诺金公司 | 苯并二氮卓衍生物的选择性磺化 |
TWI783957B (zh) | 2016-12-23 | 2022-11-21 | 美商伊繆諾金公司 | 靶向adam9之免疫共軛物及其使用方法 |
WO2018183494A1 (fr) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Conjugués anticorps-médicament ciblant cd19 |
WO2019060718A1 (fr) * | 2017-09-22 | 2019-03-28 | Immunogen, Inc. | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
CA3117493A1 (fr) | 2018-10-30 | 2020-05-07 | Immunogen, Inc. | Procedes de traitement faisant appel a des immunoconjugues anti-cd123 |
EP3880681B1 (fr) | 2018-11-12 | 2024-03-13 | ImmunoGen, Inc. | Procédés de préparation de dérivés de benzodiazépine cytotoxiques |
JP7401456B2 (ja) | 2018-11-14 | 2023-12-19 | 第一三共株式会社 | 抗cdh6抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
EP3941527A1 (fr) * | 2019-03-21 | 2022-01-26 | ImmunoGen, Inc. | Procédés de préparation de conjugués agent de liaison cellulaire-médicament |
TW202102228A (zh) | 2019-03-25 | 2021-01-16 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物結合物 |
TW202102225A (zh) | 2019-03-25 | 2021-01-16 | 日商第一三共股份有限公司 | 抗her2抗體-吡咯并苯二氮呯衍生物結合物 |
WO2020196712A1 (fr) | 2019-03-27 | 2020-10-01 | 第一三共株式会社 | Combinaison d'un conjugué anticorps-dérivé de pyrrolobenzodiazépine et d'un inhibiteur de parp |
TW202106716A (zh) | 2019-04-29 | 2021-02-16 | 美商免疫遺傳股份有限公司 | 包含抗cd123免疫結合物之治療組合 |
KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
AU2022401024A1 (en) | 2021-11-30 | 2024-05-16 | Daiichi Sankyo Company, Limited | Protease-cleavable masked antibodies |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
GB9422383D0 (en) * | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
CN100522955C (zh) | 2002-08-02 | 2009-08-05 | 伊缪诺金公司 | 含有新型强效紫杉烷的细胞毒性剂及其治疗用途 |
DE60336149D1 (de) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
JP5354835B2 (ja) | 2002-11-07 | 2013-11-27 | イミュノジェン・インコーポレーテッド | 抗cd33抗体、及びそれを用いた急性骨髄性白血病の治療方法 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
CA2652945C (fr) | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Anticorps et immuno-conjugues, et leurs utilisations |
CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
SG189811A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
AU2010210646B2 (en) * | 2009-02-05 | 2015-10-29 | Immunogen, Inc. | Novel benzodiazepine derivatives |
US8431416B2 (en) * | 2009-04-01 | 2013-04-30 | Becton, Dickinson And Company | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates |
JP5918129B2 (ja) | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 |
WO2011092838A1 (fr) | 2010-01-29 | 2011-08-04 | 株式会社フォーサイド・ドット・コム | Système de partage de contenu et procédé de partage de contenu |
NZ724971A (en) | 2010-02-24 | 2019-06-28 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
BR112012023010A8 (pt) | 2010-03-12 | 2017-12-26 | Immunogen Inc | Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37 |
WO2011131746A2 (fr) | 2010-04-20 | 2011-10-27 | Genmab A/S | Protéines contenant des anticorps fc hétérodimères et leurs procédés de production |
WO2012058588A2 (fr) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci |
WO2012058592A2 (fr) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci |
SI2675479T1 (sl) * | 2011-02-15 | 2016-04-29 | Immunogen, Inc. | Citotoksični derivati benzodiazepina |
WO2014134457A2 (fr) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
US9999680B2 (en) | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
EP2961435B1 (fr) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
CA2944784A1 (fr) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Composes conjugues comprenant des anticorps a cysteine manipulee |
KR20170063507A (ko) * | 2014-06-20 | 2017-06-08 | 어브게노믹스 인터내셔널 인코포레이티드 | Her2 항체-약물 접합체 |
JP2017528418A (ja) * | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
RU2017101681A (ru) * | 2014-06-20 | 2018-07-20 | Биоэллаенс К.В. | Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения |
EP3188761A4 (fr) * | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Procédés de formulation de compositions de conjugués anticorps-médicaments |
MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
-
2016
- 2016-06-28 MD MDE20180452T patent/MD3313845T2/ro unknown
- 2016-06-28 AU AU2016285929A patent/AU2016285929B2/en active Active
- 2016-06-28 PT PT167383223T patent/PT3313845T/pt unknown
- 2016-06-28 MA MA42250A patent/MA42250B1/fr unknown
- 2016-06-28 LT LTEP16738322.3T patent/LT3313845T/lt unknown
- 2016-06-28 KR KR1020187002729A patent/KR20180021176A/ko not_active Application Discontinuation
- 2016-06-28 RS RS20201354A patent/RS61050B1/sr unknown
- 2016-06-28 PL PL16738322T patent/PL3313845T3/pl unknown
- 2016-06-28 EP EP16738322.3A patent/EP3313845B1/fr active Active
- 2016-06-28 WO PCT/US2016/039796 patent/WO2017004025A1/fr active Application Filing
- 2016-06-28 EP EP20182141.0A patent/EP3769787A1/fr active Pending
- 2016-06-28 HU HUE16738322A patent/HUE052616T2/hu unknown
- 2016-06-28 RU RU2017144859A patent/RU2733740C2/ru active
- 2016-06-28 SI SI201630977T patent/SI3313845T1/sl unknown
- 2016-06-28 CN CN201680038492.0A patent/CN107708810B/zh active Active
- 2016-06-28 ES ES16738322T patent/ES2832527T3/es active Active
- 2016-06-28 CN CN202111168673.4A patent/CN113769108A/zh active Pending
- 2016-06-28 CA CA2988806A patent/CA2988806A1/fr active Pending
- 2016-06-28 US US15/195,269 patent/US10898579B2/en active Active
- 2016-06-28 JP JP2017568292A patent/JP6843080B2/ja active Active
- 2016-06-28 DK DK16738322.3T patent/DK3313845T3/da active
- 2016-06-29 TW TW105120514A patent/TWI740833B/zh active
- 2016-06-29 TW TW110132303A patent/TW202146057A/zh unknown
- 2016-06-29 AR ARP160101972A patent/AR106013A1/es unknown
-
2018
- 2018-10-30 HK HK18113828.1A patent/HK1254782A1/zh unknown
-
2020
- 2020-09-08 US US17/014,404 patent/US20210085800A1/en active Pending
- 2020-11-09 HR HRP20201790TT patent/HRP20201790T1/hr unknown
- 2020-11-10 CY CY20201101058T patent/CY1123606T1/el unknown
-
2021
- 2021-02-19 JP JP2021025322A patent/JP2021088581A/ja active Pending
-
2022
- 2022-03-31 AU AU2022202208A patent/AU2022202208A1/en active Pending
- 2022-08-15 JP JP2022129205A patent/JP7441281B2/ja active Active
-
2024
- 2024-02-16 JP JP2024021646A patent/JP2024067036A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42250A (fr) | Conjugués d'anticorps à cystéine modifiée | |
MA46452B1 (fr) | Composés de benzo[b]thiophéne en tant qu'agonistes de sting | |
MA46708B1 (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA38496A1 (fr) | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques | |
MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
MA44146B1 (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
PH12017500358A1 (en) | Cytotoxic benzodiazepine derivatives | |
BR112018075626A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco anticorpo | |
MA45280B1 (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
SG195172A1 (en) | Novel maytansinoid derivatives with peptide linker and conjugates thereof | |
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
LU92940I2 (en) | Pembrolizumab | |
MX2013009420A (es) | Derivados citotoxicos de la benzodiazepina. | |
MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
MA35035B1 (fr) | Anticorps polypeptidiques qui antagonisent les cd40 | |
EA202091217A1 (ru) | Конъюгат аналога тубулизина с разветвленными линкерами | |
MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA39254B2 (fr) | Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh | |
EA201070826A1 (ru) | Антитела против pcrv | |
MX2020009864A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. | |
MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. | |
FR3070831B1 (fr) | Procede de preparation d'une composition a base de proteines de legumineuses | |
WO2019078697A3 (fr) | Anticorps anti-cd3 et composition pharmaceutique destinée au traitement du cancer, contenant ledit anticorps | |
MA32029B1 (fr) | Vaccins contre la malaria | |
AU2020357395A8 (en) | Bicyclic compound and use thereof |